JP2013502209A5 - - Google Patents

Download PDF

Info

Publication number
JP2013502209A5
JP2013502209A5 JP2012525147A JP2012525147A JP2013502209A5 JP 2013502209 A5 JP2013502209 A5 JP 2013502209A5 JP 2012525147 A JP2012525147 A JP 2012525147A JP 2012525147 A JP2012525147 A JP 2012525147A JP 2013502209 A5 JP2013502209 A5 JP 2013502209A5
Authority
JP
Japan
Prior art keywords
seq
immunoconjugate
variable region
chain variable
region sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012525147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013502209A (ja
JP5764127B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/061810 external-priority patent/WO2011020783A2/en
Publication of JP2013502209A publication Critical patent/JP2013502209A/ja
Publication of JP2013502209A5 publication Critical patent/JP2013502209A5/ja
Application granted granted Critical
Publication of JP5764127B2 publication Critical patent/JP5764127B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012525147A 2009-08-17 2010-08-13 標的化イムノコンジュゲート Active JP5764127B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23458409P 2009-08-17 2009-08-17
US61/234,584 2009-08-17
EP10162410.4 2010-05-10
EP10162410 2010-05-10
PCT/EP2010/061810 WO2011020783A2 (en) 2009-08-17 2010-08-13 Targeted immunoconjugates

Publications (3)

Publication Number Publication Date
JP2013502209A JP2013502209A (ja) 2013-01-24
JP2013502209A5 true JP2013502209A5 (https=) 2013-05-16
JP5764127B2 JP5764127B2 (ja) 2015-08-12

Family

ID=43033282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012525147A Active JP5764127B2 (ja) 2009-08-17 2010-08-13 標的化イムノコンジュゲート

Country Status (21)

Country Link
US (1) US8945571B2 (https=)
EP (1) EP2467165B1 (https=)
JP (1) JP5764127B2 (https=)
KR (2) KR101588598B1 (https=)
CN (1) CN102573922B (https=)
AR (1) AR077879A1 (https=)
AU (1) AU2010285071A1 (https=)
CA (1) CA2769619C (https=)
CO (1) CO6430436A2 (https=)
CR (1) CR20120042A (https=)
EC (1) ECSP12011685A (https=)
ES (1) ES2534085T3 (https=)
IL (1) IL217844A0 (https=)
MA (1) MA33717B1 (https=)
MX (1) MX2012002014A (https=)
PE (1) PE20120630A1 (https=)
RU (1) RU2583876C2 (https=)
SG (1) SG178443A1 (https=)
TW (1) TW201119672A (https=)
WO (1) WO2011020783A2 (https=)
ZA (1) ZA201200767B (https=)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
AU2015213405B2 (en) * 2010-08-13 2017-08-03 Roche Glycart Ag Anti-FAP antibodies and methods of use
HUE036077T2 (hu) * 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
JP5841149B2 (ja) * 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー 抗テネイシンca2抗体及び使用の方法
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
MX2013009151A (es) * 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
ES2762179T3 (es) * 2011-09-26 2020-05-22 Philogen Spa Terapia de combinación de inmunocitocinas
CN104245734B (zh) 2012-01-20 2017-09-05 非营利性组织佛兰芒综合大学生物技术研究所 靶向突变体α‑螺旋束细胞因子
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AR092044A1 (es) * 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
EP2882775B1 (en) 2012-08-09 2018-02-14 Roche Glycart AG Asgpr antibodies and uses thereof
US9561275B2 (en) 2012-09-14 2017-02-07 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
WO2015007536A2 (en) 2013-07-18 2015-01-22 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
CA2918119C (en) 2013-07-19 2022-11-29 Centre Hospitalier Regional Universitaire De Montpellier Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases
DK3022226T3 (en) * 2013-07-19 2019-03-25 Vib Vzw TARGETED MODIFIED IL-1 FAMILY MEMBERS
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾tnfファミリーメンバー
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2015224576A1 (en) * 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015143004A1 (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Targeted therapeutics
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CR20170194A (es) 2014-11-14 2017-07-10 Hoffmann La Roche Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
GB201500875D0 (en) 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
JP7028643B2 (ja) * 2015-02-13 2022-03-02 エージェンシー フォー サイエンス, テクノロジー アンド リサーチ 膜を破壊しないp53活性化ステープルペプチド
WO2016156291A1 (en) * 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN109563141A (zh) * 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
MX386014B (es) 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
AU2017330338A1 (en) * 2016-09-21 2019-05-02 The Trustees Of The University Of Pennsylvania Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
SG11201903400WA (en) 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
WO2018097308A1 (ja) 2016-11-28 2018-05-31 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
WO2018114754A1 (en) * 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3580230B1 (en) * 2017-02-07 2026-04-22 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3641647A4 (en) 2017-06-20 2021-05-05 Madrigal Pharmaceuticals, Inc. TARGETED THERAPEUTICS
CN110799194A (zh) 2017-06-20 2020-02-14 马德里加尔制药公司 包含靶向治疗剂的联合疗法
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Pd-1およびpd-l1結合物質
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
CN111836828B (zh) 2017-11-28 2024-12-20 中外制药株式会社 包括抗原结合结构域和运送部分的多肽
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019222449A1 (en) * 2018-05-16 2019-11-21 Dragonfly Therapeutics, Inc. Protein binding nkg2d, cd16 and a fibroblast activation protein
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US11795203B2 (en) * 2018-07-30 2023-10-24 Jinyu Zhang Protein heterodimer and use thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12098177B2 (en) * 2018-09-07 2024-09-24 Nantbio, Inc. Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
CN120590542A (zh) 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス (ホン コン) リミテッド Il-2組成物およびその使用方法
AU2020287373B2 (en) * 2019-06-05 2026-01-29 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2020257412A1 (en) 2019-06-19 2020-12-24 Orionis Biosciences, Inc. Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
WO2021001289A1 (en) 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
TW202120537A (zh) 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
US12049488B2 (en) * 2020-04-06 2024-07-30 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
PH12022552436A1 (en) 2020-04-15 2024-01-03 Hoffmann La Roche Immunoconjugates
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
EP4198051A4 (en) * 2020-08-11 2024-05-01 Kanaph Therapeutics Inc. FUSION PROTEIN WITH IL-12 AND ANTI-FAP ANTIBODIES AND USE THEREOF
AU2021393752A1 (en) 2020-12-04 2023-05-18 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
AU2022227029A1 (en) 2021-02-26 2023-08-31 New York University Compositions and methods comprising antibodies that bind to covalent peptide conjugates
US20240262913A1 (en) 2021-03-09 2024-08-08 Hoffmann-La Roche Inc. Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
JP2024508949A (ja) 2021-03-09 2024-02-28 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
AU2022362681A1 (en) 2021-10-14 2024-04-04 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
JP2024543257A (ja) 2021-11-26 2024-11-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗tyrp1/抗cd3二重特異性抗体およびtyrp1特異性抗体の併用療法
AU2023206004B2 (en) * 2022-01-04 2025-04-17 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
EP4651885A1 (en) 2023-01-20 2025-11-26 F. Hoffmann-La Roche AG Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP1015496B1 (en) * 1997-03-05 2009-06-17 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Divalent anti-t cells immunotoxins and use thereof
EP1489100B1 (en) * 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
ATE333900T1 (de) 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
WO2001075110A2 (en) * 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
AU2006226060A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
ATE459648T1 (de) * 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
US8744844B2 (en) * 2007-07-06 2014-06-03 Audience, Inc. System and method for adaptive intelligent noise suppression
EA200802289A1 (ru) 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
WO2009017823A2 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物

Similar Documents

Publication Publication Date Title
JP5764127B2 (ja) 標的化イムノコンジュゲート
JP2013502209A5 (https=)
JP7690552B2 (ja) CD137抗原結合部位を含むFc結合断片
US12497455B2 (en) Anti-CD3E/BCMA bispecific antibody and use thereof
JP5878182B2 (ja) ミュータントインターロイキン−2ポリペプチド
JP2016531920A (ja) Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
JP2023551563A (ja) pH依存性変異体インターロイキン-2ポリペプチド
EP4534559A1 (en) Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof
EP4491631A1 (en) Anti-pd-1 antibody binding domain and immunoconjugate
EA052903B1 (ru) Антитело к cd40, биспецифическое антитело к pd-l1×cd40 и их применение
HK1169318B (en) Targeted immunoconjugates
TW202235436A (zh) Siglec-15結合蛋白的製備及其用途
HK40099163A (zh) Ph依赖性突变型白细胞介素-2多肽
BR112012003739A2 (pt) imunoconjugados, polinucleotídeo, microorganismo transgênico, método para produzir o imunoconjugado, composição e usos do imunoconjugado e da composição